The Petten High Flux Reactor (HFR) is a nuclear research reactor located in Petten, Netherlands. The HFR is on the premises of the Petten research centre and it is a high flux reactor. It is owned by the Joint Research Centre (JRC) and managed by the Nuclear Research and Consultancy Group (NRG). [1] The HFR’s original purpose was to provide experience and irradiation capabilities for the nascent Dutch nuclear power program. Construction began in 1958, and the reactor reached criticality on the 9th of November, 1961.
The construction of the HFR was one of the first contracts to be fulfilled by the Nuclear Reactor Engineering Organisation (also known as Nuclear Products - ERCO), an unincorporated division of American Car & Foundry Industries Incorporated (ACF) that formed in 1954 in order to enable ACF to enter the commercial nuclear reactor sector. The contract was signed in May 1956. [2] Under the Atoms for Peace program, an export license was granted to ACF and construction began at the site in Petten in 1958. However, in 1959 ACF sold its nuclear division to Allis-Chalmers, [3] who took over the project and commissioned the reactor, reaching criticality two years behind schedule on November 9th, 1961.
Apart from its function as a research centre, the HFR is a large producer of radioactive material for the purpose of medical diagnosis and the treatment of cancer (radiopharmaceuticals). As of 2010 [update] the nuclear facility supplied about 60% of the European demand for medical isotopes. [4] [5] Also at the high flux reactor, one of the neutron beam channels, which was originally installed for performing fundamental research, has been specially modified for the direct irradiation of patients. This allows use of neutrons for the treatment of tumors after saturation of these tumors with a pharmaceutical containing boron. [6] When hit by a weak neutron beam, boron will locally emit radiation that will destroy the tumor. This technique is mainly suitable for the treatment of brain tumors.
As of 2006 [update] , only low-enriched uranium fuel was used at the facilities in Petten. As a result of political pressure from the United States and the International Atomic Energy Agency (IAEA), research reactors are no longer allowed to use highly enriched uranium fuel because of its potential use for the production of nuclear weapons. [7] The use of highly enriched uranium targets for the production of medical isotopes was discontinued in January 2018. [8]
Its capacity was increased in steps to 45 MW (thermal) by 1970. The reactor is property of the European Commission and is operated by the Nuclear Research and Consultancy Group (NRG). [9]
As of 2024 [update] the reactor is expected to remain operational until 2030, when it will be replaced at Petten by a new high flux reactor (PALLAS).
From August 2008, the reactor was shut down due to corrosion of the pipes in its primary cooling circuit. The operator brought the plant back on-line in February 2009. [10]
The low flux reactor was first used in 1960 and permanently shut down in 2010. [11] It had a capacity of 30 kW. The reactor was property of the Nuclear Research and Consultancy Group (NRG) and mainly used for the production of neutrons for biological and physical research.
In 2009 the Argentine company INVAP (teamed with Spanish group Isolux) was pre selected in the international tender for the PALLAS project, for the procurement of an 80 MW nuclear reactor for the Dutch village of Petten, [12] but in February 2010, the Dutch radiopharmaceutical producer Nuclear Research and Consultancy Group (NRG) extended the preparatory phase up to end of the year for financing [13]
In mid-May 2014, NRG, the company that operates the reactor, asked for a bridging loan at the Dutch Ministry of Economic Affairs, because of the financial losses in the previous years. A bankruptcy could not be ruled out, if the credit would be refused. In addition, there were negotiations with the banks, because of the estimated 80 million euros, needed for the upcoming maintenance of the 50-year-old reactor. [14] [15]
Enriched uranium is a type of uranium in which the percent composition of uranium-235 has been increased through the process of isotope separation. Naturally occurring uranium is composed of three major isotopes: uranium-238, uranium-235, and uranium-234. 235U is the only nuclide existing in nature that is fissile with thermal neutrons.
Uranium-235 is an isotope of uranium making up about 0.72% of natural uranium. Unlike the predominant isotope uranium-238, it is fissile, i.e., it can sustain a nuclear chain reaction. It is the only fissile isotope that exists in nature as a primordial nuclide.
A technetium-99m generator, or colloquially a technetium cow or moly cow, is a device used to extract the metastable isotope 99mTc of technetium from a decaying sample of molybdenum-99. 99Mo has a half-life of 66 hours and can be easily transported over long distances to hospitals where its decay product technetium-99m is extracted and used for a variety of nuclear medicine diagnostic procedures, where its short half-life is very useful.
Research reactors are nuclear fission-based nuclear reactors that serve primarily as a neutron source. They are also called non-power reactors, in contrast to power reactors that are used for electricity production, heat generation, or maritime propulsion.
The SLOWPOKE is a family of low-energy, tank-in-pool type nuclear research reactors designed by Atomic Energy of Canada Limited (AECL) beginning in the late 1960s. John W. Hilborn is the scientist most closely associated with their design. They are beryllium-reflected with a very low critical mass, but provide neutron fluxes higher than available from a small particle accelerator or other radioactive sources.
A swimming pool reactor, also called an open pool reactor, is a type of nuclear reactor that has a core immersed in an open pool usually of water.
INVAP S.E. is an Argentine company that provides design, integration, construction and delivery of equipment, plants and devices. The company operates in North America, Europe, Asia Pacific, Latin America, the Middle East and Africa, and delivers projects for nuclear, aerospace, chemical, medical, petroleum and governmental sectors.
Technetium-99m (99mTc) is a metastable nuclear isomer of technetium-99, symbolized as 99mTc, that is used in tens of millions of medical diagnostic procedures annually, making it the most commonly used medical radioisotope in the world.
The Oregon State University Radiation Center (OSURC) is a research facility that houses a nuclear reactor at Oregon State University (OSU) in Corvallis, Oregon, United States. The Oregon State TRIGA Reactor (OSTR) serves the research needs of the OSU nuclear engineering department along with other departments.
The Radiation Laboratory at the University of Massachusetts Lowell serves the Department of Applied Physics among others. The laboratory contains the University of Massachusetts Lowell Research Reactor (UMLRR), a 1 MW pool-type research reactor that has been operating since 1974, along with a 300 kCi Co-60 gamma ray source and a 5.5 MeV Van de Graaff accelerator.
The Maria reactor is Poland's second nuclear research reactor and is the only one still in use. It is located at Narodowe Centrum Badań Jądrowych (NCBJ) at Świerk-Otwock, near Warsaw and named in honor of Maria Skłodowska-Curie. It is the only reactor of Polish design.
The MIT Nuclear Research Reactor (MITR) serves the research purposes of the Massachusetts Institute of Technology. It is a tank-type 6 megawatt reactor that is moderated and cooled by light water and uses heavy water as a reflector. It is the second largest university-based research reactor in the U.S. and has been in operation since 1958. It is the fourth-oldest operating reactor in the country.
The Pakistan Atomic Research Reactor or (PARR) are two nuclear research reactors and two other experimental neutron sources located in the PINSTECH Laboratory, Nilore, Islamabad, Pakistan.
The Washington State University Reactor (WSUR) is housed in the Dodgen Research Facility, and was completed in 1961. The (then) Washington State College Reactor was the brainchild of Harold W. Dodgen, a former researcher on the Manhattan Project where he earned his PhD from 1943 to 1946. He secured funding for the ambitious 'Reactor Project' from the National Science Foundation, the Atomic Energy Commission, and the College administration totaling $479,000. Dodgen's basis for constructing a reactor was that the College was primely located as a training facility for the Hanford site, as well as Idaho National Laboratory because there was no other research reactor in the West at that time. After completing the extensive application and design process with the help of contractors from General Electric they broke ground in August 1957 and the first criticality was achieved on March 7, 1961 at a power level of 1W. They gradually increased power over the next year to achieve their maximum licensed operating power of 100 kW.
Neutron capture therapy (NCT) is a type of radiotherapy for treating locally invasive malignant tumors such as primary brain tumors, recurrent cancers of the head and neck region, and cutaneous and extracutaneous melanomas. It is a two-step process: first, the patient is injected with a tumor-localizing drug containing the stable isotope boron-10 (10B), which has a high propensity to capture low energy "thermal" neutrons. The neutron cross section of 10B is 1,000 times more than that of other elements, such as nitrogen, hydrogen, or oxygen, that occur in tissue. In the second step, the patient is radiated with epithermal neutrons, the sources of which in the past have been nuclear reactors and now are accelerators that produce higher energy epithermal neutrons. After losing energy as they penetrate tissue, the resultant low energy "thermal" neutrons are captured by the 10B atoms. The resulting decay reaction yields high-energy alpha particles that kill the cancer cells that have taken up enough 10B.
Phoenix, formerly known as Phoenix Nuclear Labs, is a company specializing in neutron generator technology located in Monona, Wisconsin. Founded in 2005, the company develops nuclear and particle accelerator technologies for application in medicine, defense and energy. Phoenix has held contracts with the U.S. Army, the U.S. Department of Energy, the U.S. Department of Defense and the U.S. Air Force. Phoenix developed a proprietary gas target neutron generator technology and has designed and built a number of particle accelerator-related technologies.
A High Flux Reactor is a type of nuclear research reactor.
The Ghana Research Reactor-1 (GHARR-1) is a nuclear research reactor located in Accra, Ghana and is the only nuclear reactor in the country. It is operated by the National Nuclear Research Institute, a sub-division of the Ghana Atomic Energy Commission. The reactor is a commercial version of the Chinese Miniature Neutron Source Reactor (MNSR) design. The reactor had its first criticality on December 17, 1994.
FiR 1 was Finland's first nuclear reactor. It was a research reactor that was located in the Otaniemi campus area in the city of Espoo. The TRIGA Mark II reactor had a thermal power of 250 kilowatts. It started operation in 1962, and it was permanently shut down in 2015. At first, the reactor was operated by Helsinki University of Technology (TKK), and since 1971 by VTT Technical Research Centre of Finland.
The Nigeria research reactor (NIRR-1) is a nuclear research reactor located in Zaria, Nigeria. The reactor is located at the Centre for Energy Research and Training (CERT), part of Ahmadu Bello University. The reactor had its first criticality in 2004, launched by the then director of CERT, Prof. Ibrahim Musa Umar and is the only nuclear reactor currently operating in Nigeria.